Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer

Gut

Volumn 66, Issue 4, 2017, Pages 654-664

  Hur, Keun ^a,b,c   Toiyama, Yuji ^a,d   Okugawa, Yoshinaga ^a   Ide, Shozo ^d   Imaoka, Hiroki ^d   Boland, C Richard ^a   Goel, Ajay ^a  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b Kyungpook National University School of Medicine   (South Korea)

^c Kyungpook National University   (South Korea)

^d MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 203; UNCLASSIFIED DRUG; MIRN203 MICRORNA, HUMAN; TUMOR MARKER;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INDEPENDENT VARIABLE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CANCER STAGING; COLORECTAL TUMOR; GENETICS; LIVER TUMOR; NUDE MOUSE; PATHOLOGY; PERITONEUM TUMOR; PREDICTIVE VALUE; PROGNOSIS; SECONDARY; VALIDATION STUDY;

AGED; ANIMALS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; UP-REGULATION;

EID: 84954306021     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308737     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844-57.
3. Halama N, Herrmann C, Jaeger D, et al. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer. Anticancer Res 2008;28:4111-5.
4. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007;25:180-6.
5. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677-83.
6. Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med 2005;56:139-56.
7. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
8. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 2011;6:e17745.
9. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
10. Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 2012;256:544-51.
11. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
12. Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010;25:1674-80.
13. Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013;105:849-59.
14. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 2012;36:e61-7.
15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
16. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
17. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10:126-39.
18. Jou J, Diehl AM. Epithelial-mesenchymal transitions and hepatocarcinogenesis. J Clin Invest 2010;120:1031-4.
19. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-29.
20. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-9.
21. Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 12 2010;285:35293-302.
22. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
23. Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013;62:1315-26.
24. Moes M, Le Bechec A, Crespo I, et al. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS ONE 2012;7:e35440.
25. Qu Y, Li WC, Hellem MR, et al. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer 2013;133:544-55.
26. Saini S, Majid S, Yamamura S, et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res 2011;17:5287-98.
27. Zhang Z, Zhang B, Li W, et al. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer 2011;2:782-91.
28. Ruopp MD, Perkins NJ, Whitcomb BW, et al. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J 2008;50:419-30.
29. Diao Y, Guo X, Jiang L, et al. miR-203, a tumor suppressor frequently downregulated by promoter hypermethylation in rhabdomyosarcoma. J Biol Chem 2014;289:529-39.
30. Zhu X, Er K, Mao C, et al. miR-203 suppresses tumor growth and angiogenesis by targeting VEGFA in cervical cancer. Cell Physiol Biochem 2013;32:64-73.
31. Furuta M, Kozaki KI, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010;31:766-76.
32. Arndt GM, Dossey L, Cullen LM, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009;9:374.
33. Chiang Y, Song Y, Wang Z, et al. Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J Gastrointest Surg 2011;15:63-70.
34. Earle JS, Luthra R, Romans A, et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 2010;12:433-40.
35. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
36. Monzo M, Navarro A, Bandres E, et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 2008;18:823-33.
37. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36.
38. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61.
39. Toiyama Y, Hur K, Tanaka K, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 2014;259:735-43.